Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis
Prof Mendel E Singer, David C Kaelber, Maria J Antonelli
Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-218500
Table 1 Proportion of patients taking hydroxychloroquine: COVID-19 vs two control groups COVID-19 Influenza/ pneumonia/LRI CI for difference (COVID-19 vs I/P/LRI) Any outpatient visit CI for difference (COVID-19 vs OP) Age 18 and over No of patients, N 16 869 198 114 3 970 695 Lupus or RA on an immunosuppressant, N 159 2609 32 599 Hydroxychloroquine, % (N) 34.6% (55) 31.4% (819) (−4.4% to 10.8%) p=0.4290 32.7% (10 645) (−5.5% to 9.4%) p=0.6115 Age 18-64 No of patients, N 13 327 128 280 2 715 365 Lupus or RA on an immunosuppressant, N 121 1477 20 256 Hydroxychloroquine, % (N) 37.2% (45) 37.0% (547) (−8.8% to 9.1%) p=1.0000 36.9% (7473) (−8.3% to 8.9%) p=1.0000 I/P/LRI, influenza/pneumonia/other lower respiratory infection; LRI, lower respiratory infection; OP, outpatient; RA, rheumatoid arthritis.
References
Arshad, Kilgore, Chaudhry, Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis,
doi:10.1016/j.ijid.2020.06.099Bozzalla Cassione, Zanframundo, Biglia, COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-217717Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2012410Gendebien, Frenckell, Ribbens, Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-218244Magagnoli, Narendran, Pereira, Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, medRxiv,
doi:10.1016/j.medj.2020.06.001Rosenberg, Dufort, Udo, Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state, JAMA,
doi:10.1001/jama.2020.8630Tang, Cao, Han, Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial, BMJ
DOI record:
{
"DOI": "10.1136/annrheumdis-2020-218500",
"ISSN": [
"0003-4967",
"1468-2060"
],
"URL": "http://dx.doi.org/10.1136/annrheumdis-2020-218500",
"alternative-id": [
"10.1136/annrheumdis-2020-218500"
],
"author": [
{
"ORCID": "http://orcid.org/0000-0002-3331-3340",
"affiliation": [],
"authenticated-orcid": false,
"family": "Singer",
"given": "Mendel E",
"sequence": "first"
},
{
"affiliation": [],
"family": "Kaelber",
"given": "David C",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Antonelli",
"given": "Maria J",
"sequence": "additional"
}
],
"container-title": "Annals of the Rheumatic Diseases",
"container-title-short": "Ann Rheum Dis",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"bmj.com"
]
},
"created": {
"date-parts": [
[
2020,
8,
5
]
],
"date-time": "2020-08-05T21:20:37Z",
"timestamp": 1596662437000
},
"deposited": {
"date-parts": [
[
2023,
9,
27
]
],
"date-time": "2023-09-27T13:11:16Z",
"timestamp": 1695820276000
},
"indexed": {
"date-parts": [
[
2023,
9,
28
]
],
"date-time": "2023-09-28T09:51:24Z",
"timestamp": 1695894684039
},
"is-referenced-by-count": 8,
"issue": "9",
"issued": {
"date-parts": [
[
2020,
8,
5
]
]
},
"journal-issue": {
"issue": "9",
"published-online": {
"date-parts": [
[
2022,
8,
11
]
]
},
"published-print": {
"date-parts": [
[
2022,
9
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://bmj.com/coronavirus/usage",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
8,
5
]
],
"date-time": "2020-08-05T00:00:00Z",
"timestamp": 1596585600000
}
}
],
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2020-218500",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "239",
"original-title": [],
"page": "e161-e161",
"prefix": "10.1136",
"published": {
"date-parts": [
[
2020,
8,
5
]
]
},
"published-online": {
"date-parts": [
[
2020,
8,
5
]
]
},
"published-print": {
"date-parts": [
[
2022,
9
]
]
},
"publisher": "BMJ",
"reference": [
{
"DOI": "10.1136/annrheumdis-2020-217480",
"doi-asserted-by": "publisher",
"key": "2023092706101180000_81.9.e161.1"
},
{
"DOI": "10.1101/2020.04.10.20060558",
"doi-asserted-by": "crossref",
"key": "2023092706101180000_81.9.e161.2",
"unstructured": "Tang W , Cao Z , Han M , et al . Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. BMJ 2020:369."
},
{
"DOI": "10.1056/NEJMoa2012410",
"article-title": "Observational study of hydroxychloroquine in hospitalized patients with Covid-19",
"author": "Geleris",
"doi-asserted-by": "crossref",
"first-page": "2411",
"journal-title": "N Engl J Med",
"key": "2023092706101180000_81.9.e161.3",
"volume": "382",
"year": "2020"
},
{
"DOI": "10.1001/jama.2020.8630",
"article-title": "Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state",
"author": "Rosenberg",
"doi-asserted-by": "crossref",
"journal-title": "JAMA",
"key": "2023092706101180000_81.9.e161.4",
"year": "2020"
},
{
"article-title": "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19",
"author": "Magagnoli",
"journal-title": "medRxiv",
"key": "2023092706101180000_81.9.e161.5",
"year": "2020"
},
{
"DOI": "10.1016/j.ijid.2020.06.099",
"doi-asserted-by": "publisher",
"key": "2023092706101180000_81.9.e161.6"
},
{
"key": "2023092706101180000_81.9.e161.7",
"unstructured": "FDA approved drug products: hydroxychloroquine oral tablets. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf [Accessed 8 Jul 2020]."
},
{
"DOI": "10.1136/annrheumdis-2020-217717",
"doi-asserted-by": "publisher",
"key": "2023092706101180000_81.9.e161.8"
},
{
"DOI": "10.1136/annrheumdis-2020-218244",
"doi-asserted-by": "publisher",
"key": "2023092706101180000_81.9.e161.9"
},
{
"DOI": "10.1136/annrheumdis-2020-218068",
"doi-asserted-by": "publisher",
"key": "2023092706101180000_81.9.e161.10"
}
],
"reference-count": 10,
"references-count": 10,
"relation": {},
"resource": {
"primary": {
"URL": "https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2020-218500"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"General Biochemistry, Genetics and Molecular Biology",
"Immunology",
"Immunology and Allergy",
"Rheumatology"
],
"subtitle": [],
"title": "Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1136/crossmarkpolicy",
"volume": "81"
}
